How to Help Your Patients Find Rifaximin in Stock: A Provider's Guide

Your Patients Need Rifaximin — Here's How to Help Them Get It

As a prescriber, you know that writing a prescription for Rifaximin (Xifaxan) doesn't guarantee your patient will actually receive the medication. In 2026, intermittent stock-outs at retail pharmacies remain a common complaint from patients who depend on Rifaximin for hepatic encephalopathy, IBS-D, and other gastrointestinal conditions.

This guide offers a practical, step-by-step approach to help your practice navigate Rifaximin availability issues — from identifying pharmacies with stock to managing alternatives when the drug simply can't be found.

For a broader overview of the supply situation, see our provider briefing: Rifaximin Shortage: What Providers Need to Know in 2026.

Current Availability Landscape

Rifaximin is manufactured exclusively by Salix Pharmaceuticals (Bausch Health) and sold under the brand name Xifaxan. No generic exists in the US, and none is expected until 2029. The medication is available in two strengths:

• 200 mg tablets — for traveler's diarrhea
• 550 mg tablets — for hepatic encephalopathy and IBS-D

The 550 mg formulation is the one most commonly affected by availability issues, as it's used for chronic and recurring conditions requiring ongoing or repeated treatment.

Most supply disruptions occur at the retail pharmacy level rather than at the manufacturer or distributor level. Pharmacies, particularly large chains, often maintain minimal Rifaximin inventory due to its high acquisition cost ($1,800 to $2,400 per 60 tablets).

Why Your Patients Can't Find It

Understanding the root causes helps you counsel patients and adjust your prescribing workflow:

1. Single-source brand: With only one manufacturer and no generic competition, any fluctuation in supply or demand creates immediate gaps at the pharmacy level.
2. Cost-driven inventory practices: High-cost medications are often ordered on-demand rather than pre-stocked, meaning a 24-48 hour delay is common even when supply exists at the distributor.
3. Prior authorization delays: Patients may face 3 to 7 day PA turnaround times. If the PA expires before the patient fills the prescription, the process restarts.
4. Growing demand: Increased prescribing for IBS-D (FDA-approved) and SIBO (off-label) has steadily expanded the patient population competing for the same limited supply.
5. Patient awareness gaps: Many patients don't know they can check multiple pharmacies, use specialty pharmacies, or access manufacturer assistance programs.

What Providers Can Do: 5 Practical Steps

Step 1: Direct Patients to Medfinder

Medfinder for Providers offers real-time pharmacy availability data for Rifaximin. You can integrate this into your patient discharge workflow — when you prescribe Rifaximin, direct the patient (or your staff) to check Medfinder before heading to the pharmacy. This prevents wasted trips and reduces patient frustration.

Step 2: Build Relationships With Specialty Pharmacies

Identify 2-3 specialty or independent pharmacies in your area that reliably stock Rifaximin. Develop a working relationship with these pharmacies so you can route prescriptions directly to them. Many specialty pharmacies that serve gastroenterology and hepatology patients maintain standing Rifaximin inventory.

Step 3: Authorize Early Refills

For patients on chronic Rifaximin therapy (hepatic encephalopathy), authorize refills 5 to 7 days before the expected run-out date. This gives the pharmacy time to order stock if needed and prevents the patient from experiencing a gap in therapy — which can be clinically dangerous for hepatic encephalopathy patients.

Step 4: Streamline Prior Authorization

Maintain a standardized prior authorization template for Rifaximin that includes:

• Confirmed diagnosis with ICD-10 codes
• Previous treatments tried (e.g., Lactulose for HE, dietary modification for IBS-D)
• Clinical rationale for Rifaximin over alternatives
• Documentation of treatment response if this is a refill/continuation

Having this template ready reduces PA turnaround from days to hours in many cases.

Step 5: Connect Patients With Cost-Reduction Programs

Cost is a major reason prescriptions go unfilled. Ensure your patients know about:

• Xifaxan Savings Card: Reduces copay to $0-$75 for commercially insured patients
• Bausch Health Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients
• Discount card programs: SingleCare, GoodRx (limited savings on brand medications)

Your front-desk staff or care coordinators can share these resources at the time of prescribing. For a patient-friendly guide, direct them to: How to Save Money on Rifaximin.

Alternative Medications When Rifaximin Is Unavailable

When a patient truly cannot access Rifaximin, have a documented alternative protocol ready:

For Hepatic Encephalopathy

• Lactulose: First-line therapy; most patients can tolerate it with proper dose titration (target 2-3 soft stools/day). Cost: under $30/month.
• Neomycin: Short-term alternative; effective but carries risk of nephrotoxicity and ototoxicity with prolonged use. Reserve for bridge therapy.

For IBS-D

• Eluxadoline (Viberzi): FDA-approved for IBS-D; contraindicated in patients without a gallbladder or with history of pancreatitis.
• Alosetron (Lotronex): FDA-approved for severe IBS-D in women; requires enrollment in restricted prescribing program.

For SIBO

• Metronidazole: Most commonly used alternative; 250-500 mg TID for 7-14 days. Effective but with more systemic side effects.
• Ciprofloxacin: Second-line option; use cautiously given FDA black box warning for fluoroquinolone-associated adverse events.

For a patient-facing overview of alternatives, see: Alternatives to Rifaximin.

Workflow Tips for Your Practice

Integrate these steps into your standard workflow to proactively manage Rifaximin access:

• At prescribing: Check Medfinder or have staff verify pharmacy stock before the patient leaves. Send the prescription to a pharmacy that has it.
• At follow-up: Ask patients about fill difficulties at every visit. If they're consistently struggling, switch their pharmacy to a specialty or independent option.
• For new patients: Submit prior authorization on the same day you write the prescription. Don't wait for a denial — proactive PA saves days.
• For chronic patients: Set up refill reminders in your EHR 7 days before the expected fill date.
• For cost-burdened patients: Have care coordinators assist with Xifaxan Savings Card enrollment and Patient Assistance Program applications at intake.

Final Thoughts

Rifaximin access challenges in 2026 are a practical reality that affects patient outcomes. The barriers — single-source manufacturing, high cost, insurance hurdles, and limited pharmacy inventory — require a proactive, systematic response from prescribers.

By directing patients to Medfinder, building specialty pharmacy relationships, streamlining prior authorizations, and maintaining clear alternative therapy protocols, your practice can significantly reduce the number of patients who go without this important medication.

For cost-saving resources to share with patients, see: How to Help Patients Save Money on Rifaximin.